By [Journalist Name/News Desk]
October 15, 2025
I. Main Facts: Redefining the Narrative of Stage 4 Breast Cancer
The landscape of oncology is undergoing a seismic shift, moving from a binary of "cured" or "terminal" toward a more nuanced reality of long-term disease management. At the center of this evolution is the experience of patients like Miriam Sabo, whose 2019 diagnosis of Stage 4 breast cancer—specifically de novo metastatic breast cancer (MBC)—highlights both the gravity of the disease and the burgeoning hope provided by modern medical advancements.
Metastatic breast cancer, also known as Stage 4, occurs when cancer cells spread beyond the breast and nearby lymph nodes to distant organs, such as the bones, lungs, brain, or liver. While approximately 30% of women diagnosed with early-stage breast cancer will eventually see their disease metastasize, a smaller, distinct group—roughly 6% of all new diagnoses—are "de novo" cases. These patients are diagnosed with Stage 4 from the very beginning, often without any prior history of the disease.
For Sabo, diagnosed at the age of 42, the revelation was not merely a medical crisis but a total reconfiguration of her identity. Unlike the "warrior" narrative often associated with early-stage breast cancer, where patients undergo aggressive treatment with the goal of reaching a "cancer-free" milestone, MBC patients face a different reality: a "non-curative" diagnosis. This term, which Sabo prefers over "terminal," signifies a condition that cannot be eradicated but can be managed through continuous, lifelong treatment.
II. Chronology: A Six-Year Journey of Resilience and Milestones
The timeline of Miriam Sabo’s journey provides a profound case study in the longevity now possible for some MBC patients.
- Initial Diagnosis (Spring 2019): At age 42, Sabo received the news that she had breast cancer that had already spread to her liver. The "de novo" status meant there was no period of "early detection" or localized treatment; she entered the medical system as a Stage 4 patient.
- The Search for Support (2019): Recognizing the unique cultural and medical needs of her situation, Sabo reached out to Sharsheret, a national non-profit organization supporting Jewish women and families facing breast and ovarian cancer. Having previously consulted them regarding BRCA testing (for which she tested negative), she re-engaged with their specialized "Embrace" program.
- Stabilization and Adaptation (2019–2022): Through a combination of targeted therapies and systemic treatments, Sabo entered a phase of "stable disease." During this period, she worked closely with Rachel, a Sharsheret social worker, to process the psychological trauma of a "non-curative" diagnosis and the anxiety of "forever treatment."
- Transition to Peer Advocacy (2023): Encouraged by the Sharsheret leadership, including Bonnie, the head of the Embrace program, Sabo transitioned from a service recipient to a peer supporter. She began mentoring other women navigating the complexities of MBC, focusing on the mental shift required to live with a chronic, life-threatening illness.
- The Present Day (October 2025): Six and a half years after her initial diagnosis, Sabo continues to defy the "expiration date" often associated with Stage 4 statistics. She has witnessed her four children reach adulthood, attending graduations and celebrating the marriages of two of her children—milestones that seemed statistically improbable at the moment of her diagnosis.
III. Supporting Data: The Statistics of Survival and the Liver-Dominant Profile
To understand the context of Sabo’s journey, one must look at the broader epidemiological data surrounding MBC. According to the National Cancer Institute (NCI) and the SEER (Surveillance, Epidemiology, and End Results) database, the five-year relative survival rate for metastatic breast cancer has been steadily improving.
In the early 1990s, the five-year survival rate for MBC was approximately 18%. By 2025, due to the advent of CDK4/6 inhibitors, HER2-targeted therapies, and immunotherapy, that number has climbed significantly, with some subsets of patients seeing survival rates closer to 30–38%.
Key Data Points:
- De Novo vs. Recurrent: Patients diagnosed de novo often have slightly better outcomes than those whose cancer recurs after previous treatments, as their tumors have not yet developed resistance to common therapies.
- Organ Involvement: Liver metastasis, which Sabo manages, represents a significant clinical challenge. The liver is a vital organ for detoxification and metabolism; however, modern localized treatments (such as radioembolization or ablation) combined with systemic therapy have allowed for longer periods of stabilization.
- The "6.5 Year" Benchmark: Sabo’s survival of 6.5 years places her in the upper percentiles of MBC patients. While the median survival for MBC is often cited between 2 to 3 years, "long-term survivors" or "exceptional responders" are becoming more common in the clinical setting.
Medical professionals increasingly emphasize that statistics are "aggregates of the past" and do not account for the most recent breakthroughs or individual biological responses. This aligns with Sabo’s personal motto: "I’m not milk; there’s no expiration date stamped on me."
IV. Official Responses: The Role of Community-Specific Support
The role of organizations like Sharsheret is critical in bridging the gap between clinical oncology and the lived experience of the patient. Sharsheret’s "Embrace" program, which Sabo credits as a cornerstone of her "cancer team," is designed specifically for the unique needs of those living with advanced disease.
The Embrace Program Framework:
- Social Work Integration: Specialized social workers provide "sounding boards" for the specific existential dread associated with MBC—often called "scanxiety"—the fear accompanying the regular imaging required to monitor tumor growth.
- Cultural Competency: For patients in the Jewish community, Sharsheret provides a framework that respects religious traditions and family structures, which can be a vital source of strength for patients like Sabo who rely heavily on their faith.
- Peer Support Networks: By pairing newly diagnosed patients with veterans like Sabo, organizations create a "living proof" model. This counteracts the isolation often felt by MBC patients, who may feel alienated by the "survivor" culture of early-stage breast cancer awareness campaigns.
Sharsheret’s leadership emphasizes that the goal of metastatic support is not "beating" the cancer in the traditional sense, but "living well" with it. This involves managing side effects, maintaining quality of life, and finding meaning in the "day-in and day-out moments" that Sabo highlights as her primary focus.
V. Implications: The Shift from "Fighter" to "Chronic Patient"
Miriam Sabo’s story has broader implications for how society and the medical community view Stage 4 cancer. Her rejection of the "terminal" label in favor of "non-curative" reflects a growing movement within the patient advocacy community to change the language of the disease.
1. The Linguistic Shift
The traditional "war" metaphor—fighting, winning, losing—is often viewed as harmful by the MBC community. If the cancer is non-curative, the "fight" never ends, which can lead to psychological exhaustion. By framing the disease as a chronic condition, similar to Type 1 diabetes or heart disease, patients can focus on longevity and quality of life rather than an elusive "cure."
2. The Invisibility of Metastatic Patients
October is Breast Cancer Awareness Month, often dominated by pink ribbons and stories of "survivorship." However, MBC advocates point out that "awareness" of breast cancer is high, but awareness of the lethality of the disease (metastasis) remains low. Sabo’s narrative brings visibility to the 100% of breast cancer deaths that occur due to metastasis, emphasizing that the "6%" of de novo patients deserve a seat at the table.
3. The Psychological Impact on Family
Sabo’s ability to "be there" for her four children illustrates the profound impact of medical stability on the family unit. The "forever treatment" model allows parents to remain present for developmental milestones, though it requires a constant balancing act between medical appointments and family life.
4. Faith and Resilience
For many patients, the medical journey is inextricably linked to a spiritual one. Sabo’s reliance on her faith—the belief that "G-d’s plans are always for good"—serves as a psychological buffer against the uncertainty of her prognosis. In the journalistic and medical context, this highlights the importance of "whole-person care," where a patient’s spiritual and emotional needs are treated with the same priority as their physical symptoms.
Conclusion: A Legacy of "Forever"
As Miriam Sabo moves past the 6.5-year mark, her story stands as a testament to the changing face of oncology. While MBC remains a serious and life-altering diagnosis, the narrative is no longer solely one of decline. It is a narrative of persistence, of attending weddings, of mentoring others, and of living a life that refuses to be defined by a statistical expiration date.
The implications for the medical community are clear: as more patients live longer with metastatic disease, the demand for comprehensive support systems, specialized mental health care, and culturally competent advocacy will only continue to grow. Sabo’s journey from a terrified 42-year-old to a seasoned peer supporter exemplifies the potential for MBC patients to not only survive but to lead lives of profound impact and purpose.
About the Author
